Brighter AB (publ) announced that it has delivered the first batch of Actiste® devices and consumables to the UK's Salford Royal Hospital. The delivery is in preparation for the previously announced clinical research with the Northern Care Alliance NHS Foundation Trust in the City of Salford. With this high-level clinical research Brighter aims to evaluate the medical impact and disclose scientifically relevant insights about the potential benefits that Actiste® Diabetes Management as a Service can provide for the management of both type 1 and type 2 insulin-treated diabetes.

The positive results with Actiste® gained from the user-experience research in Sweden have also been published in the UK scientific journal “Cardiovascular Endocrinology & Metabolism” under the title “Actiste diabetes management as a service innovation – impact on everyday life – Swedish patients experience assessed by validated MedTech20 questionnaire”.